Sagimet Biosciences Series Company Z Score Analysis
Sagimet Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
Sagimet Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Sagimet Biosciences is extremely important. It helps to project a fair market value of Sagimet Stock properly, considering its historical
fundamentals such as Z Score. Since Sagimet Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sagimet Biosciences' historical
financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sagimet Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Based on the company's disclosures, Sagimet Biosciences Series has a Z Score of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as
Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
| | Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
Sagimet Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sagimet Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sagimet Biosciences' managers, analysts, and investors. Sagimet Fundamentals
About Sagimet Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sagimet Biosciences Series's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sagimet Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Sagimet Biosciences Series based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Sagimet Stock Analysis
When running Sagimet Biosciences' price analysis, check to
measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to
predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.